PTPRC and melanoma: However, the effect if the combination therapy on the growth of 1014 NRASmut melanoma xenografts was less than that observed with the B16F10 xenografts, though SX-682 increased the CD69+CD8+ activated T cells and decreased the CD11b+CD45+ myeloid cells, including Ly6G+CD11b+ granulocytes (and/or gMDSCs) in 1014 tumors similar to that observed in the B16F10 tumors.